By Professor Richard Bryan Lock

Preprints

Rokita JL; Rathi KS; Cardenas MF; Upton KA; Jayaseelan J; Cross KL; Pfeil J; Ritenour LE; Modi A; Farrel A; Way GP; Kendsersky NM; Patel K; Lopez G; Vaksman Z; Mayoh C; Nance J; Mccoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm JW; Marshall GM; Tyrrell V; Kalletla K; Braun FK; Qi L; Du Y; Zhang H; Lindsay HB; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan AC; Leraas KM; Coppens SE; Doddapaneni H; Momin Z; Zhang W; Sacks GI; Hart LS; Krytska K; Mosse YP; Gatto GJ; Sanchez Y; Greene CS; Diskin SJ; Vaske OM; Haussler D; Gastier-Foster JM; Kolb EA; Gorlick R; Li X-N; Reynolds CP; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Raman P; Wheeler DA; Maris JM, 2019, Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design, http://dx.doi.org/10.2139/ssrn.3377367

Wakefield C; Doolan EL; Fardell JE; Signorelli C; Veronica QF; Tucker KM; Patenaude AF; Marshall GM; Lock RB; Georgiou G; Cohn RJ, 2018, The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer Care, http://dx.doi.org/10.2139/ssrn.3260779

Germon ZP; Sillar JR; Mannan A; Duchatel RJ; Staudt D; Murray HC; Findlay IJ; Jackson ER; McEwen HP; Douglas AM; McLachlan T; Schjenken JE; Skerrett-Bryne DA; Huang H; Melo-Braga MN; Plank MW; Alvaro F; Chamberlain J; De Iuliis G; Aitken RJ; Nixon B; Wei AH; Enjeti AK; Lock RB; Larsen MR; Lee H; de Bock CE; Verrills NM; Dun MD, Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies, http://dx.doi.org/10.1101/2022.03.09.483687

Fordham AM; Brown LM; Mayoh C; Salib A; Barger ZA; Wong M; Sian TCCLK; Xie J; Gunther K; Trebilcock P; Terry RL; Barahona P; Ajuyah P; Sherstyuk A; Avila A; Cadiz R; Perkins CM; Gifford AJ; Mao J; Zhao A; O’Regan LP; Gorgels D; Lau LM; Ziegler DS; Haber M; Tyrrell V; Lock RB; Cowley MJ; Nicholls W; Daly RJ; Ekert PG; Fleuren ED, Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across pediatric and AYA sarcomas, http://dx.doi.org/10.1101/2023.07.19.548825

Truong P; Shen S; Joshi S; Islam I; Zhong L; Raftery MJ; Afrasiabi A; Alinejad-Rokny H; Nguyen M; Zou X; Bhuyan GS; Sarowar CH; Ghodousi ES; Stonehouse O; Mohamed S; Toscan CE; Connerty P; Kakadia PM; Bohlander SK; Michie KA; Larsson J; Lock RB; Walkley CR; Thoms JAI; Jolly CJ; Pimanda JE, Genome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and SUMOylation Blockade in MDS/AML, http://dx.doi.org/10.1101/2024.04.17.589858

Rokita JL; Rathi KS; Cardenas MF; Upton KA; Jayaseelan J; Cross KL; Pfeil J; Ritenour LE; Modi A; Farrel A; Way GP; Kendsersky NM; Patel K; Lopez G; Vaksman Z; Mayoh C; Nance J; McCoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm JW; Marshall GM; Tyrrell V; Kalletla K; Braun FK; Qi L; Du Y; Zhang H; Lindsay HB; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan AC; Leraas KM; Coppens SE; Doddapaneni H; Momin Z; Zhang W; Sacks GI; Hart LS; Krytska K; Mosse YP; Gatto GJ; Sanchez Y; Greene CS; Diskin SJ; Vaske OM; Haussler D; Gastier-Foster JM; Kolb EA; Gorlick R; Li X-N; Reynolds CP; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Raman P; Wheeler DA; Maris JM, Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design, http://dx.doi.org/10.1101/566455

Ziegler D; Lau L; Khuong-Quang D-A; Mayoh C; Wong M; Barahona P; Ajuyah P; Senapati A; Nagabushan S; Sherstyuk A; Altekoester A-K; Fuentes-Bolanos N; Yeung V; Sullivan A; Diamond Y; Omer N; Jessop S; Battaglia L; Zhukova N; Cui L; Lin A; Gifford A; Fleuren E; Dalla-Pozza L; Moore A; Khaw S; Eisenstat D; Gottardo N; Wood P; Tapp H; Alvaro F; McCowage G; Nicholls W; Hansford J; Manoharan N; Kotecha R; Mateos M; Lock R; Tyrrell V; Haber M; Trahair T; Cowley M; Ekert P; Marshall G, Precision-guided treatment improves outcomes for children with high-risk cancers, http://dx.doi.org/10.21203/rs.3.rs-3376668/v1

Jing D; Beck D; Cao H; Tian F; Huang Y; Zhao H; Tai X; XU W; Kosasih H; Kealy D; Bridge K; Zhao W; Holding A; Dowle A; Taylor S; Song G; Fajardo D; Walia Y; Wang M; Zhang C; Wang J; Mi J-Q; Lock R; de Bock C, PU.1 Eviction at Lymphocyte-Specific Chromatin Domains Mediates Glucocorticoid Response in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.21203/rs.3.rs-3872306/v1

Tremblay C; Saw J; Yan F; Boyle J; Amarasinghe O; Abdollahi S; Vo NQA; Shields B; Mayoh C; McCalmont H; Evans K; Steiner A; Parsons K; McCormack M; Powell D; Wong N; Jane S; Lock R; Curtis D, Targeting LMO2-induced autocrine FLT3 signalling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia, http://dx.doi.org/10.21203/rs.3.rs-4608404/v1

Back to profile page